Substituted piperidine compounds and methods of their use
AssigneeAdolor Corporation
InventorsRoland Ellwood Dolle, Bertrand Le Bourdonnec
Life of this patent
Estimating the term…
Abstract
Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.
Claims55
A compound of formula I:
- wherein:
- R1 is —C(═O)OR5, —C(═O)NR6R7, or —NR6R7;
- R2 and R3 are each independently alkyl or alkenyl;
- R4 is:
- H,
- cycloalkyl,
- heterocycloalkyl, or
- C1-10 alkyl which is substituted with at least one:
- substituted aryl, wherein at least one of said aryl substituents is other than OH, nitro, amino, halo, CN, CH2CN, CONH2, C1-4 alkyl, C1-4 alkoxy, or C1-5 alkanoyl (which latter three groups are optionally substituted by one or more halo atoms),
- aryloxyaryl,
- -aryl-N(H)Rb,
- -aryl-N(Rb)Rb,
- heteroarylaryl,
- alkoxyaryl, wherein the carbon chain of said alkoxy is interrupted by a nitrogen atom,
- substituted alkoxyaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo,
- substituted cycloalkyl,
- RS(═O)p substituted heteroaryl,
- RS(═O)p substituted heterocycloalkyl,
- RS(═O)p substituted aryl,
- heterocycloalkylheteroaryl,
- heteroarylheteroaryl,
- bicycloalkyl,
- bicycloalkenyl,
- carboxy,
- —CO2Ra,
- —C(═O)N(R6a)—R6b—CO2H,
- —C(═O)N(R6a)—R6b—CO2R,
- —C(═O)N(R6a)—R6b—C(═O)NR7aR7b,
- —N(R7c)C(═O)R7d,
- —N(R7c)S(═O)2R7d,
- aralkoxyaryl,
- substituted arylheteroaryl, or
- substituted alkoxyheteroaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo;
- p is 0, 1, or 2;
- R is alkyl, aralkyl, or aryl;
- Ra is H, alkyl, alkenyl, cycloalkyl, aryl, or heteroaryl, provided that Ra is not C1-6 alkyl;
- each Rb is independently alkyl, cycloalkyl, aralkyl, or aryl,
- R6a is H, alkyl, aralkyl, cycloalkyl, alkenyl, aryl, heteroaralkyl, or heteroaryl;
- R6b is lower alkylene, or lower aralkylene or, together with the nitrogen atom to which they are attached, R6a and R6b form a 4- to 7-membered heterocycloalkyl ring;
- R7a and R7b are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl, or together with the nitrogen atom to which they are attached, R7a and R7b form a 4- to 7-membered heterocycloalkyl ring, provided that at least one of R7a and R7b is other than H;
- R7c and R7d are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl;
- R5 is H or alkyl;
- and
- each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R, and provided that when R1 is NR6R7, R4 can also be aralkyl;
- provided that when R4 is H and R2 and R3 are each independently alkyl, then R1 is —C(═O)NR6R7 or —NR6R7, wherein at least one of R6 and R7 is —C(═O)R, or, R6 and R7 taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycloalkyl ring;
- or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.
A compound selected from the group consisting of:
- 3-(3R,4R-dimethyl-piperidin-4-yl)-benzoic acid;
- 3-(3R,4R-dimethyl-[1,4′]bipiperidinyl-4-yl)-benzoic acid;
- and
- 3-(3R,4R-dimethyl-piperidin-4-yl)-benzamide;
- or a pharmaceutically acceptable salt thereof.
A method of binding opioid receptors in a patient in need thereof, comprising the step of:
- administering to said patient a therapeutically effective amount of a compound according of formula Ib:
- wherein:
- R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
- R2 and R3 are each independently alkyl or alkenyl;
- R4 is:
- H,
- cycloalkyl,
- heterocycloalkyl, or
- C1-10 alkyl which is substituted with at least one:
- substituted aryl, wherein at least one of said aryl substituents is other than OH, nitro, amino, halo, CN, CH2CN, CONH2, C1-4 alkyl, C1-4 alkoxy, or C1-5 alkanoyl (which latter three groups are optionally substituted by one or more halo atoms),
- aryloxyaryl,
- -aryl-N(H)Rb,
- -aryl-N(Rb)Rb,
- heteroarylaryl,
- alkoxyaryl, wherein the carbon chain of said alkoxy is interrupted by a nitrogen atom,
- substituted alkoxyaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo,
- substituted cycloalkyl,
- RS(═O)p substituted heteroaryl,
- RS(═O)p substituted heterocycloalkyl,
- RS(═O)p substituted aryl,
- heterocycloalkylheteroaryl,
- heteroarylheteroaryl,
- bicycloalkyl,
- bicycloalkenyl,
- carboxy,
- —CO2Ra,
- —C(═O)N(R6a)—R6b—CO2H,
- —C(═O)N(R6a)—R6b—CO2R,
- —C(═O)N(R6a)—R6b—C(═O)NR7aR7b,
- —N(R7c)C(═O)R7d,
- —N(R7c)S(═O)2R7d,
- aralkoxyaryl,
- substituted arylheteroaryl, or
- substituted alkoxyheteroaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo;
- p is 0, 1, or 2;
- R is alkyl, aralkyl, or aryl;
- Ra is H, alkyl, alkenyl, cycloalkyl, aryl, or heteroaryl, provided that Ra is not C1-6 alkyl;
- each Rb is independently alkyl, cycloalkyl, aralkyl, or aryl,
- R6a is H, alkyl, aralkyl, cycloalkyl, alkenyl, aryl, heteroaralkyl, or heteroaryl;
- R6b is lower alkylene, or lower aralkylene or, together with the nitrogen atom to which they are attached, R6a and R6b form a 4- to 7-membered heterocycloalkyl ring;
- R7a and R7b are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl, or together with the nitrogen atom to which they are attached, R7a and R7b form a 4- to 7-membered heterocycloalkyl ring, provided that at least one of R7a and R7b is other than H;
- R7c and R7d are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl;
- R5 is H or alkyl;
- and
- each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R, and provided that when R1 is NR6R7, R4 can also be aralkyl;
- or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.
A pharmaceutical composition, comprising:
- a pharmaceutically acceptable carrier;
- and
- a therapeutically effective amount of a compound of formula Ic:
- wherein:
- R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
- R2 and R3 are each independently alkyl or alkenyl;
- R5 is H or alkyl;
- each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R;
- and
- R is alkyl, aralkyl, or aryl;
- or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.
A method for preventing or treating gastrointestinal dysfunction, comprising the step of:
- administering to a patient in need thereof an effective amount of a compound of formula Ic:
- wherein:
- R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
- R2 and R3 are each independently alkyl or alkenyl;
- R5 is H or alkyl;
- each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R and
- R is alkyl, aralkyl, or aryl;
- or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.
A method for preventing or treating ileus, comprising the step of:
- administering to a patient in need thereof an effective amount of a compound of formula Ic
- wherein:
- R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
- R2 and R3 are each independently alkyl or alkenyl;
- R5 is H or alkyl;
- each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R;
- and
- R is alkyl, aralkyl, or aryl;
- or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.
A method for treating or preventing a side effect associated with an opioid, comprising the step of:
- administering to a patient in need thereof an effective amount of a compound of formula Ic
- wherein:
- R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
- R2 and R3 are each independently alkyl or alkenyl;
- R5 is H or alkyl;
- each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R;
- and
- R is alkyl, aralkyl, or aryl;
- or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.
A method of preventing or treating pain, comprising the step of:
- administering to a patient in need thereof an effective amount of an opioid;
- and
- an effective amount of a compound of formula Ic:
- wherein:
- R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
- R2 and R3 are each independently alkyl or alkenyl;
- R5 is H or alkyl;
- each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R;
- and
- R is alkyl, aralkyl, or aryl;
- or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.
Dependencies are inferred from the claim text.